Key Takeaways
- • Private equity healthcare deals nationwide declined 18.5% year-over-year (Q2 2025 to Q2 2026), with management services organization (MSO) deals dropping nearly 36% from 111 to 71 transactions, according to PitchBook research published in August 2026.
- • Oregon's 2025 law prohibits corporate entities and private equity firms from owning local health clinics through MSO structures and blocks the "friendly physician" model, wherein out-of-state physicians nominally own clinical practices while PE firms control administrative and billing operations.
- • Increased state-level regulatory scrutiny is directly slowing PE healthcare acquisition timelines and deal velocity nationwide, with Oregon's legislation cited as part of a broader cascade of restrictive state laws limiting corporate takeover of medical practices.
- • The Oregon law represents one of the nation's most comprehensive restrictions on corporate practice of medicine (CPOM), establishing barriers that fundamentally disrupt traditional PE healthcare acquisition strategies that historically relied on MSO structures.
Summary
A new PitchBook industry report released in August 2026 documents a significant nationwide slowdown in private equity healthcare acquisitions, with Oregon's 2025 law identified as a key contributor to declining deal activity. The report found that total PE healthcare services deals decreased 18.5% year-over-year from the second quarter of 2025 through the second quarter of 2026. More dramatically, deals specifically targeting management services organization arrangements—the primary acquisition vehicle for PE-backed healthcare consolidation—plummeted 36%, falling from 111 to 71 transactions over the same period.
The decline reflects mounting state-level regulatory pressure on PE investment strategies in healthcare. According to the PitchBook analysis, "tighter regulations slowing deal processes" represent a material headwind, with multiple states implementing laws designed to restrict corporate influence over local healthcare providers. Oregon's 2025 legislation stands out as particularly restrictive. The law explicitly prohibits ownership of local health clinics through MSO structures and bars MSOs from obtaining majority control or ownership of clinical practices. Critically, the statute eliminates the "friendly physician" model—a longstanding PE workaround wherein out-of-state physicians affiliated with PE firms nominally own the clinical entity while PE-backed management companies retain control of administrative, billing, and operational functions.
This structural prohibition directly attacks the standard PE acquisition model in healthcare, where management companies acquire control over practice operations while maintaining separation between clinical (physician-owned) and administrative ownership. By blocking this arrangement, Oregon's law forces PE investors to either abandon healthcare deals entirely or fundamentally restructure acquisition approaches. The legislation represents among the nation's most comprehensive restrictions on corporate practice of medicine, establishing barriers that industry observers characterize as unprecedented in scope.
The timing of this regulatory wave creates immediate strategic implications for PE managers evaluating healthcare portfolios and pipeline opportunities. Declining transaction velocity signals either deal deferrals, market exit strategies, or resource reallocation toward less-regulated subsectors of healthcare services. For institutional investors and LPs, this regulatory environment introduces both execution risk on existing healthcare fund commitments and potential yield compression as PE firms compete for remaining compliant deal structures in states with less restrictive frameworks.
The decline reflects mounting state-level regulatory pressure on PE investment strategies in healthcare. According to the PitchBook analysis, "tighter regulations slowing deal processes" represent a material headwind, with multiple states implementing laws designed to restrict corporate influence over local healthcare providers. Oregon's 2025 legislation stands out as particularly restrictive. The law explicitly prohibits ownership of local health clinics through MSO structures and bars MSOs from obtaining majority control or ownership of clinical practices. Critically, the statute eliminates the "friendly physician" model—a longstanding PE workaround wherein out-of-state physicians affiliated with PE firms nominally own the clinical entity while PE-backed management companies retain control of administrative, billing, and operational functions.
This structural prohibition directly attacks the standard PE acquisition model in healthcare, where management companies acquire control over practice operations while maintaining separation between clinical (physician-owned) and administrative ownership. By blocking this arrangement, Oregon's law forces PE investors to either abandon healthcare deals entirely or fundamentally restructure acquisition approaches. The legislation represents among the nation's most comprehensive restrictions on corporate practice of medicine, establishing barriers that industry observers characterize as unprecedented in scope.
The timing of this regulatory wave creates immediate strategic implications for PE managers evaluating healthcare portfolios and pipeline opportunities. Declining transaction velocity signals either deal deferrals, market exit strategies, or resource reallocation toward less-regulated subsectors of healthcare services. For institutional investors and LPs, this regulatory environment introduces both execution risk on existing healthcare fund commitments and potential yield compression as PE firms compete for remaining compliant deal structures in states with less restrictive frameworks.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.